Cargando…
Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto de Medicina Tropical
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679679/ https://www.ncbi.nlm.nih.gov/pubmed/29116287 http://dx.doi.org/10.1590/S1678-9946201759067 |
_version_ | 1783277629864935424 |
---|---|
author | Grando, Aline Vitali Ferreira, Paulo Roberto Abrão Pessôa, Mário Guimarães Mazo, Daniel Ferraz de Campos Brandão-Mello, Carlos Eduardo Reuter, Tânia Martinelli, Ana de Lourdes Candolo Gonzalez, Mário Peribanez Nastri, Ana Catharina Seixas-Santos Campos, Aléia Faustina Lopes, Max Igor Banks Ferreira Brito, José David Urbaez Mendes-Corrêa, Maria Cássia |
author_facet | Grando, Aline Vitali Ferreira, Paulo Roberto Abrão Pessôa, Mário Guimarães Mazo, Daniel Ferraz de Campos Brandão-Mello, Carlos Eduardo Reuter, Tânia Martinelli, Ana de Lourdes Candolo Gonzalez, Mário Peribanez Nastri, Ana Catharina Seixas-Santos Campos, Aléia Faustina Lopes, Max Igor Banks Ferreira Brito, José David Urbaez Mendes-Corrêa, Maria Cássia |
author_sort | Grando, Aline Vitali |
collection | PubMed |
description | Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups. |
format | Online Article Text |
id | pubmed-5679679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Instituto de Medicina Tropical |
record_format | MEDLINE/PubMed |
spelling | pubmed-56796792017-11-16 Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus Grando, Aline Vitali Ferreira, Paulo Roberto Abrão Pessôa, Mário Guimarães Mazo, Daniel Ferraz de Campos Brandão-Mello, Carlos Eduardo Reuter, Tânia Martinelli, Ana de Lourdes Candolo Gonzalez, Mário Peribanez Nastri, Ana Catharina Seixas-Santos Campos, Aléia Faustina Lopes, Max Igor Banks Ferreira Brito, José David Urbaez Mendes-Corrêa, Maria Cássia Rev Inst Med Trop Sao Paulo Original Article Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups. Instituto de Medicina Tropical 2017-11-06 /pmc/articles/PMC5679679/ /pubmed/29116287 http://dx.doi.org/10.1590/S1678-9946201759067 Text en https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Grando, Aline Vitali Ferreira, Paulo Roberto Abrão Pessôa, Mário Guimarães Mazo, Daniel Ferraz de Campos Brandão-Mello, Carlos Eduardo Reuter, Tânia Martinelli, Ana de Lourdes Candolo Gonzalez, Mário Peribanez Nastri, Ana Catharina Seixas-Santos Campos, Aléia Faustina Lopes, Max Igor Banks Ferreira Brito, José David Urbaez Mendes-Corrêa, Maria Cássia Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus |
title | Peginterferon still has a place in the treatment of hepatitis C caused by
genotype 3 virus |
title_full | Peginterferon still has a place in the treatment of hepatitis C caused by
genotype 3 virus |
title_fullStr | Peginterferon still has a place in the treatment of hepatitis C caused by
genotype 3 virus |
title_full_unstemmed | Peginterferon still has a place in the treatment of hepatitis C caused by
genotype 3 virus |
title_short | Peginterferon still has a place in the treatment of hepatitis C caused by
genotype 3 virus |
title_sort | peginterferon still has a place in the treatment of hepatitis c caused by
genotype 3 virus |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679679/ https://www.ncbi.nlm.nih.gov/pubmed/29116287 http://dx.doi.org/10.1590/S1678-9946201759067 |
work_keys_str_mv | AT grandoalinevitali peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT ferreirapaulorobertoabrao peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT pessoamarioguimaraes peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT mazodanielferrazdecampos peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT brandaomellocarloseduardo peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT reutertania peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT martinellianadelourdescandolo peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT gonzalezmarioperibanez peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT nastrianacatharinaseixassantos peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT camposaleiafaustina peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT lopesmaxigorbanksferreira peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT britojosedavidurbaez peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus AT mendescorreamariacassia peginterferonstillhasaplaceinthetreatmentofhepatitisccausedbygenotype3virus |